Orexo AB has signed an agreement granting Mundipharma Pty Ltd. (Mundipharma Australia) the exclusive rights to commercialize Orexo’s lead product, Zubsolv, for the treatment of opioid dependence, in Australia and New Zealand.
Mundipharma Australia supported Orexo in obtaining marketing authorization for Zubsolv in Australia. Orexo will now be responsible for product supply and Mundipharma Australia will take responsibility for commercialization of Zubsolv in Australia and New Zealand. Orexo will receive royalties on future sales and the launch is expected 1H20.

Zubsolv is used for the treatment of opioid dependence as part of a comprehensive treatment plan including counselling and psychosocial support. It is commercialized by Orexo in the U.S. Zubsolv is also approved in Europe where partnering discussions are on-going.

“We have worked closely with Mundipharma in Australia for the last year to prepare for the launch of Zubsolv in Australia, and I am pleased we have reached an agreement to continue this partnership. In recent months, we have also been working intensively to establish a streamlined supply chain for Zubsolv outside the US to enable access to this new efficient treatment option. Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for the successful launch of Zubsolv, providing important treatment options for patients where they are needed most.” said Nikolaj Sørensen, President and CEO of Orexo AB.

“Mundipharma has worked closely with clinicians across Australia for more than 20 years and these connections have helped highlight the growing need for treatments that help reduce harms associated with opioid misuse and abuse,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. “Earlier this year we began providing the potentially life-saving opioid overdose reversal nasal spray, Nyxoid®, so I’m proud that we can also now help Australians access this important treatment for opioid dependence,” continued Jane Orr.